🔍

SUPRIYA - Supriya Lifesci.

📊 NSE: SUPRIYA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:55

📢 Recent Corporate Announcements

Supriya Lifescience Clarifies Single Segment Operations Following NSE Query

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Mar 2026, 03:41 PM

Supriya Lifescience has responded to a clarification request from the National Stock Exchange regarding its financial results for the quarter ended December 31, 2025. The exchange had questioned the absence of segment-wise reporting in the initial filing made on February 09, 2026. The company clarified that it operates exclusively in a single business segment, which is Pharmaceuticals. The omission in the digital portal was attributed to a technical error during the submission process rather than a lack of disclosure intent.

NSE sought clarification on March 10, 2026, regarding missing segment details in the Q3 FY26 results.
Company confirms it operates in a single business segment: Pharmaceuticals.
The omission was identified as a technical error during the digital submission of 'Quick Results' on the exchange portal.
Management reaffirmed commitment to SEBI (LODR) Regulations, 2015 and accurate future disclosures.

💡 No action is required as this is a procedural regulatory clarification with no impact on the company's financial health or business operations.

Supriya Lifescience Seeks Approval for Three Independent Director Appointments

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 10 Mar 2026, 03:41 PM

Supriya Lifescience Limited has initiated a postal ballot to seek shareholder approval for the appointment of three Independent Directors. The company is proposing the appointment of Mr. Manish Panchal and Mr. Kothandaraman Hari for five-year terms effective from February 9, 2026. Additionally, the board seeks to re-appoint Dr. Neelam Arora for a second five-year term starting March 25, 2026. The e-voting process for these special resolutions will run from March 11, 2026, to April 10, 2026.

Appointment of Mr. Manish Panchal as Independent Director for a 5-year term ending February 2031
Appointment of Mr. Kothandaraman Hari as Independent Director for a 5-year term ending February 2031
Re-appointment of Dr. Neelam Arora for a second 5-year term starting March 25, 2026
E-voting period scheduled from March 11, 2026, to April 10, 2026
Cut-off date for eligibility to vote is February 27, 2026

💡 These are routine corporate governance appointments. Investors should monitor the voting results on April 11, 2026, but no immediate action is required.

Supriya Lifescience Q3 FY26: Revenue Grows 11% to ₹206 Cr, Maintains 20% Growth Guidance

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 17 Feb 2026, 10:47 AM

Supriya Lifescience reported a steady Q3 FY26 with revenue increasing 11% YoY to ₹206 crores and a PAT of ₹50 crores. The company maintained a strong EBITDA margin of 34.9%, supported by high-margin niche products and an 82% export contribution. Management reaffirmed its 20% annual revenue growth guidance and the ₹1,000 crore revenue milestone target for FY27. Key growth drivers include the launch of cardiovascular and ADHD products and the upcoming capitalization of the Ambernath facility in Q4 FY26.

Q3 FY26 revenue rose 11% YoY to ₹206 crores with an EBITDA margin of 34.9% (₹72 crores).
Exports contributed 82% of total revenue, led by LatAm (24%) and North America (6%).
Ambernath facility is ready for capitalization in Q4 FY26, which is a key milestone for the CDMO segment.
Management maintains FY26 guidance of 20% revenue growth and 33-35% EBITDA margins.
Backward integration initiatives supported 74% of revenues, strengthening the overall cost structure.

💡 Investors should monitor the scale-up of new cardiovascular and ADHD products in Q4, which are expected to drive the guided 20% annual growth. The capitalization of the Ambernath facility remains a key trigger for the expansion of the CDMO business.

Supriya Lifescience Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 10 Feb 2026, 04:23 PM

Supriya Lifescience Limited has officially released the audio recording of its earnings conference call held on February 10, 2026. The call focused on the company's operational and financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement following the announcement of quarterly results. Investors can access the recording via the company's investor relations website to understand management's perspective on recent performance.

Audio recording of the earnings call held on February 10, 2026, is now available for public access.
The call discussed financial results for the quarter and nine months ended December 31, 2025.
The recording is hosted on the company's official website under the financial section.
This filing follows previous intimations sent to exchanges on February 4 and February 9, 2026.

💡 Investors should listen to the recording to gain insights into management's outlook on API market trends and margin guidance. No immediate trading action is required based on this administrative update.

Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹206.4 Cr; PAT at ₹49.7 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 01:05 PM

Supriya Lifescience reported a steady 11.2% YoY revenue growth for Q3 FY26, reaching ₹206.44 crore, driven by strong demand in the anesthetic segment and expansion in Latin American markets. While EBITDA grew by 9.3% to ₹72.08 crore, margins saw a slight contraction to 34.9% from 35.5% in the previous year. Net profit increased by 6.2% YoY to ₹49.68 crore, supported by a high export contribution of 82%. The company is preparing for the commercial launch of its Ambernath formulation facility in Q4 FY26 and has acquired land for future expansion.

Revenue grew 11.2% YoY to ₹206.44 crore, while PAT increased 6.2% to ₹49.68 crore.
Anesthetic segment contribution rose to 54% of total revenues in 9M FY26 from 48% YoY.
Capacity utilization improved to 76% in 9M FY26, up from 70% in the previous fiscal year.
Geographic diversification improved with North America share doubling to 6% and LatAm rising to 24%.
Acquired three new land parcels and scheduled Ambernath facility launch for Q4 FY26.

💡 Investors should monitor the successful commissioning of the Ambernath facility in Q4 FY26 as a key growth catalyst. The stock remains attractive due to high margins and strong export presence, though margin stabilization should be watched.

Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹2,064 Mn; PAT Grows 6.2%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:58 PM

Supriya Lifescience reported a steady performance for Q3 FY26, with revenue from operations growing 11.2% YoY to ₹2,064.4 million. While EBITDA increased by 9.3% to ₹720.8 million, margins saw a slight compression of 61 bps to 34.9% due to higher employee and other expenses. The company continues to strengthen its backward integration, which now accounts for 74% of 9M FY26 revenue. Key growth drivers include the expansion into Liquid Anesthesia and the upcoming commissioning of the Ambernath FDF facility in H2 FY26.

Revenue from operations grew 11.2% YoY to ₹2,064.4 Mn in Q3 FY26.
EBITDA stood at ₹720.8 Mn with a margin of 34.9%, while PAT grew 6.2% YoY to ₹496.8 Mn.
Anesthetics segment dominated the therapy mix, contributing 54% to 9M FY26 revenue.
Export markets remain strong, contributing 82% of total revenue in Q3 FY26.
Total reactor capacity reached 932 KLPD with the addition of the 335 KLPD Block E.

💡 Investors should monitor the ramp-up of the newly commissioned Block E and the upcoming Ambernath FDF facility for margin improvement. The company's strong backward integration and leadership in niche APIs provide a competitive moat.

Supriya Lifescience Appoints New Independent Directors and Reconstitutes Board Committees

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 09 Feb 2026, 07:38 PM

Supriya Lifescience has strengthened its board by appointing two new Additional Independent Directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms effective February 9, 2026. Mr. Hari brings significant capital markets expertise as a former Executive Vice President at the NSE, while Mr. Panchal offers over 32 years of experience in the chemical and pharma sectors. The company also re-appointed Dr. Neelam Yashpal Arora for a second five-year term as an Independent Woman Director. These appointments coincide with the approval of the unaudited financial results for the quarter ended December 31, 2025.

Appointment of Mr. Kothandaraman Hari (former NSE EVP) as Additional Independent Director for a 5-year term.
Appointment of Mr. Manish Panchal (Business Leader with 32+ years experience) as Additional Independent Director for a 5-year term.
Re-appointment of Dr. Neelam Yashpal Arora as Independent Woman Director for a second term from 2026 to 2031.
Reconstitution of the Audit, Nomination and Remuneration, and Stakeholders’ Relationship Committees.
Board approval of unaudited financial results for the quarter and nine months ended December 31, 2025.

💡 Investors should view the addition of a capital markets veteran and a strategy expert to the board as a positive step for corporate governance. While the management changes are routine, shareholders should focus on the Q3 FY26 financial results to assess the company's current growth trajectory.

Supriya Lifescience Appoints Former NSE EVP to Board; Approves Q3 FY26 Results

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 09 Feb 2026, 07:25 PM

Supriya Lifescience has approved its unaudited financial results for the quarter ended December 31, 2025, alongside significant board-level appointments. The company has inducted Mr. Kothandaraman Hari, a former Executive VP at the National Stock Exchange (NSE) with 28 years of experience, and Mr. Manish Panchal, a veteran in the pharma and chemical sectors, as Independent Directors. Additionally, Dr. Neelam Yashpal Arora was re-appointed for a second five-year term. These moves, including the reconstitution of key board committees, signal a strong push toward enhanced corporate governance and strategic oversight.

Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, a capital markets veteran and former NSE Executive VP, as an Independent Director for 5 years.
Appointed Mr. Manish Panchal, with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term effective March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent leadership.

💡 The addition of a high-profile capital markets veteran from the NSE to the board is a positive indicator for corporate governance and institutional credibility. Investors should view these leadership changes as a strategic move to strengthen the company's market positioning and compliance framework.

Supriya Lifescience Appoints New Independent Directors and Approves Q3 FY26 Results

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 09 Feb 2026, 07:17 PM

Supriya Lifescience's board met on February 09, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The company announced the re-appointment of Dr. Neelam Yashpal Arora and the induction of two new independent directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms. Mr. Hari brings significant capital markets expertise from his 28-year tenure at the National Stock Exchange (NSE). These appointments aim to strengthen corporate governance and strategic oversight as the company reconstitutes its key board committees.

Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, former Executive VP at NSE, as an Additional Independent Director for a 5-year term.
Appointed Mr. Manish Panchal, a business leader with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term starting March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent members.

💡 Investors should review the detailed Q3 FY26 financial statements to assess the company's growth trajectory. The addition of high-caliber professionals from the NSE and the pharma industry to the board is a positive sign for governance and strategic planning.

Supriya Lifescience Schedules Q3 FY26 Earnings Call for February 10, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 04 Feb 2026, 12:45 PM

Supriya Lifescience Limited has scheduled its earnings conference call for February 10, 2026, at 11:00 AM IST to discuss the financial results for Q3 FY26. The call will cover the company's operational performance for the quarter and nine-month period ending December 31, 2025. Senior management, including the Executive Chairman and Managing Director, will lead the discussion and answer investor questions. This is a routine regulatory notification following the disclosure of quarterly financial results.

Earnings call scheduled for February 10, 2026, at 11:00 AM IST.
Focus on financial performance for the quarter and nine months ended December 31, 2025.
Top management including Executive Chairman Dr. Satish Wagh and MD Dr. Saloni Wagh will participate.
International dial-in numbers available for investors in Singapore, Hong Kong, UK, and USA.

💡 Investors should track the management commentary during the call for updates on new product launches and capacity utilization. No immediate portfolio changes are recommended based on this scheduling notice.

Supriya Lifescience Clarifies Segment Reporting and Filing Delay for Q2 FY26 Results

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 03 Feb 2026, 12:06 PM

Supriya Lifescience has responded to NSE's clarification request regarding its financial results filed on November 12, 2025. The company clarified that the absence of segment reporting was a typographical error, as it operates solely in the Pharmaceuticals segment. Additionally, the delay in filing results beyond the mandatory 30-minute window was attributed to internal technical glitches during the upload process. The company has since implemented additional internal checks to prevent such administrative lapses in the future.

Confirmed the company operates in a single business segment, namely Pharmaceuticals.
Attributed the omission of segment details in the Nov 12, 2025 filing to an inadvertent typographical error.
Explained the filing delay beyond the 30-minute SEBI deadline as a result of internal technical system difficulties.
Stated that multiple upload attempts were made before the issue was resolved and filing completed.
Implemented additional internal checks to ensure future compliance with SEBI (LODR) Regulations.

💡 No action is required as these are minor administrative and technical clarifications. Investors should remain focused on the company's core pharmaceutical business performance.

Supriya Lifescience Submits SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 04:11 PM

Supriya Lifescience Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that share certificates received for dematerialization were processed and cancelled as per regulatory requirements. This filing ensures that the company's register of members is accurately updated with depository names. Such filings are standard procedural requirements for all listed entities in India to maintain transparency in shareholding records.

Confirmed compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Report covers the specific quarter ending December 31, 2025.
Registrar MUFG Intime India Private Limited verified that dematerialized securities are listed on stock exchanges.
Confirmation that security certificates were mutilated and cancelled after due verification within prescribed timelines.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial results for fundamental performance indicators.

Supriya Lifescience Assigned IND A+/Positive Rating for Rs 1,140 Cr Bank Facilities

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 30 Dec 2025, 03:39 PM

India Ratings and Research (Ind-Ra) has assigned credit ratings to Supriya Lifescience Limited's bank loan facilities totaling Rs. 1,140 crore. The company received a long-term rating of 'IND A+' with a 'Positive' outlook and a short-term rating of 'IND A1'. This assignment indicates a strong credit profile and the 'Positive' outlook suggests potential for future upgrades. The rating reflects the company's ability to manage its significant banking facilities effectively.

India Ratings and Research assigned ratings to bank loan facilities worth Rs. 1,140 crore
Long-term rating assigned as 'IND A+' with a 'Positive' outlook
Short-term rating assigned as 'IND A1' for the specified facilities
The rating action was officially communicated on December 30, 2025

💡 The positive outlook and strong credit ratings are favorable indicators of financial health and may lead to lower borrowing costs. Investors should monitor the company's execution to see if the positive outlook leads to a rating upgrade in the future.

Supriya Lifescience to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Dec 2025, 11:34 PM

Supriya Lifescience Limited has announced the closure of its trading window for all insiders and designated persons starting January 1, 2026. This is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations ahead of the company's financial results declaration. The closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the results are officially announced to the exchanges.

Trading window closure starts from Thursday, January 01, 2026
Closure is in anticipation of Q3 and nine-month financial results ending December 31, 2025
Window to reopen 48 hours after the declaration of financial results
Applies to all designated persons and their immediate relatives as per SEBI norms

💡 This is a routine compliance notification and requires no immediate action from retail investors. Investors should monitor for the upcoming board meeting date announcement to track the company's Q3 performance.

View All SUPRIYA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company reported revenue from operations of INR 200 crores for Q2 FY '26, representing a 20% year-on-year growth compared to INR 166 crores in Q2 FY '25. Sequentially, revenue grew by 38%. Historical revenue has grown from INR 3,912 million in FY21 to INR 6,965 million in FY25.

Geographic Revenue Split

Exports are the cornerstone of the business, accounting for 81% of total revenue in Q2 FY '26. Foreign exchange earnings for the year ended March 31, 2025, were INR 5,286 million compared to INR 4,498.14 million in the previous year.

Profitability Margins

The company reported a PAT of INR 50.43 crores for Q2 FY '26 with a PAT margin of 25.2%. For the half-year ended September 30, 2025, PAT stood at INR 85.22 crores. Management guides for a stabilized margin of 33%-35% in the midterm as products transition from semi-regulated to regulated markets.

EBITDA Margin

EBITDA for Q2 FY '26 was INR 73 crores, a 12% year-on-year increase and 41% sequential increase. The EBITDA margin for the quarter was 36%, which is in line with management guidance.

Capital Expenditure

Capital expenditure has increased significantly, with FY25 capex spend at INR 1,623 million. As of September 30, 2025, Capital Work in Progress (CWIP) stood at INR 1,725 million, up from INR 1,480 million in March 2025. Property, plant, and equipment were valued at INR 4,519 million.

Credit Rating & Borrowing

ICRA upgraded the short-term rating to [ICRA]A1 from [ICRA]A2+. The company maintains a healthy leverage profile with a Debt/Equity ratio of 0.01 as of FY25. Total equity stood at INR 10,818 million as of September 2025.

⚙️ Operational Drivers

Manufacturing Efficiency

Management emphasizes 'execution excellence' and 'operational efficiency' as strategic levers to sustain growth and navigate operational challenges effectively.

📈 Strategic Growth

New Products/Services

The company is launching new products in regulated markets and is bringing a finished formulation business on stream to add to margins.

Market Expansion

The strategy involves scaling up in semi-regulated markets and maturing products into regulated markets where entry barriers are higher and pricing is better.

Strategic growth analysis not yet available for this company.